This week, eight biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
This week, La Jolla Pharmaceutical Company (LJPC) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.
This week, Adamas Pharmaceuticals, Inc. (ADMS) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). For more information, get Portfolio Grader’s complete analysis of ADMS stock.
The rating of Incyte Corporation (INCY) moves up this week, rising from a C to a B. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.
This week, Ambit Biosciences Corp. (AMBI) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AMBI stock.
The rating of GTx, Inc. (GTXI) moves up this week, rising from a C to a B. GTx discovers, develops, and commercializes therapeutics primarily related to the treatment of serious men’s health conditions. For more information, get Portfolio Grader’s complete analysis of GTXI stock.
Progenics Pharmaceuticals, Inc. (PGNX) earns a B this week, jumping up from last week’s grade of C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
Celladon Corporation (CLDN) improves from a B to an A rating this week. For more information, get Portfolio Grader’s complete analysis of CLDN stock.
Galapagos NV Sponsored ADR (GLPG) is seeing ratings go up from a B last week to an A this week. For more information, get Portfolio Grader’s complete analysis of GLPG stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
